ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1372

Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study

Désirée van der Heijde1, Jürgen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Endokrinologikum Berlin, Berlin, Germany, 4UCB Pharma, Braine, Belgium, 5UCSD School of Medicine, La Jolla, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy, certolizumab pegol and spondylarthropathy, Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients’ (pts) work productivity.1 The impact of the entire spectrum of axSpA on work productivity is still poorly researched. RAPID-axSpA (NCT01087762) is the first report of the effect of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, on paid and household work productivity, and daily activities, in pts with axSpA.

Methods:

Recruited pts had adult-onset active axSpA as defined by the ASAS criteria,1 BASDAI ≥4, spinal pain ≥4 on a 10 point scale, CRP > upper limit of normal or sacroillitis on MRI. Pts must have failed ≥1 NSAID. Up to 40% of pts could have experienced secondary failure to 1 previous anti-TNF. The pt population reflected the broad axSpA population, including AS pts also meeting the modified New York criteria and nr-axSpA pts who met the ASAS MRI or clinical criteria. Pts were randomized 1:1:1 to PBO, or CZP 400mg at Week (Wk) 0, 2 and 4 (loading dose, LD) followed by either CZP 200mg every 2 wks (Q2W) or CZP 400mg every 4 wks (Q4W). Pts receiving PBO who failed to achieve an ASAS20 response at both Wks 14 and 16 were rescued and randomized at Wk16 to receive CZP 200mg Q2W or CZP 400mg Q4W following LD.  The arthritis-specific Work Productivity Survey (WPS) assessed the impact of axSpA on workplace and household productivity. WPS was administered every 4 wks. WPS responses (last observation carried forward imputation) were compared between treatment arms using a non-parametric bootstrap-t method.

Results:

325 pts were randomized. 63.2%, 69.4%, and 74.8% of pts in the PBO, CZP 200mg Q2W, and CZP 400mg Q4W treatment groups were employed at study BL; 11%-13% of pts were unable to work due to axSpA; 4%-9% were students; 3%-8% were retired. Treatment groups were comparable at BL in terms of workplace and household productivity. At BL the burden of axSpA on absenteeism, presenteeism, household productivity and social activities was high (Table). Compared to PBO, pts employed in both CZP groups reported reduced absenteeism, presenteeism, and axSpA interference with work from Wk4 through to Wk24 (Table). CZP groups also reported greater reductions vs PBO in days lost of household work and of family/social/leisure activities per month, in days with reduced household productivity and in axSpA interference with household duties as early as Wk4 through to Wk 24 (Table).

Conclusion:  

CZP improved workplace productivity in pts with axSpA by reducing absenteeism, presenteeism and axSpA interference with work. CPZ also improved household productivity and increased participation in social and daily activities.

References:

  1. Boonen A, Ann Rheum Dis 2010;69:6 1123-1128
  2. Rudwaleit M, Ann Rheum Dis 2009;68:6 770-776.

Table. Work and household productivity in RAPID-axSpA study (FAS population, LOCF data)

Description: AS Productivity_Table


Disclosure:

D. van der Heijde,

UCB Pharma,

5,

UCB Pharma,

2,

UCB Pharma,

8;

J. Braun,

UCB Pharma,

5,

UCB Pharma,

2,

UCB Pharma,

8;

M. Rudwaleit,

UCB Pharma,

5;

O. Purcaru,

UCB Pharma,

3;

A. Kavanaugh,

UCB Pharma,

5,

UCB Pharma,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-participation-in-daily-activities-after-24-weeks-of-certolizumab-pegol-treatment-of-axial-spondyloarthritis-patients-including-patients-with-ankylosing-spondylitis-results-of-a-phase-3-dou/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology